Category:

Tobacco and e-cigarette companies have been accused of using the COVID-19 crisis to advertise e-cigarettes on social media and “undermine minimum age purchase restrictions” that protect minors...The not-for-profit activist group Campaign for Tobacco-Free Kids analysed the marketing tactics of big tobacco, e-cigarette and vaping companies in 28 countries, including the UK...It found that on social media, the two largest tobacco companies – Philip Morris International and British American Tobacco – had appropriated ‘Stay at home’ hashtags used by governments and health authorities to market heated cigarette products, such as Glo and iQOS, and e-cigarettes, including Vype...READ MORE

Some drugmakers work for years to take one of their meds from launch to blockbuster status––a journey defined by competition, the market, branding and a dash of luck. But even for pharma's biggest whales, growth-minded executives have a question: What have you done for me lately?...we here at FiercePharma have compiled a list of top 10 drugs by estimated sales increase in 2020––a group comprising some of the most successful launches in recent years, with a few surprises thrown in as well...READ MORE
1. Keytruda
2. Biktarvy
3. Revlimid
4. Eliquis
5. Ozempic
6. Dupixent
7. Tagrisso
8. Imbruvica
9. Ocrevus
10. Stelara

Is the pharma industry hiking up drug prices to boost profitability at the expense of hardworking Americans? That question—a favorite of politicians on both sides of the aisle—is at the heart of a special issue of the Journal of the American Medical Association, which features a collection of articles that aim to provide a well-rounded answer...Perhaps the most damning of the studies compares the profits of the 35 biggest pharmaceutical companies to the S&P 500 as a whole. The study...found that between 2000 and 2018 the median annual gross profit margin of Big Pharma was 76.5%, versus just 37.4% for the S&P 500 companies. Earnings before taxes and net income margins were also significantly higher among pharma companies, the authors reported...Merck CEO Kenneth Frazier had his own set of worries about the new JAMA studies, though he was more focused on fairness—or lack thereof...READ MORE

Although drug shortages due to the novel coronavirus disease outbreak haven’t occurred yet, the FDA and pharmacists are closely watching for potential shortages. Separately, pharmacists should urge Americans to get flu vaccinations and take a cautious approach with coronavirus…“While our primary concern is the health and safety of those affected by the virus, ASHP is concerned with the vulnerability of the pharmaceutical supply chain to threats like the coronavirus outbreak,” Michael Ganio, PharmD, BCPS, director of pharmacy practice and quality at ASHP...An estimated 80% of active pharmaceutical ingredient used in the US market comes from foreign sources. In addition, the FDA has recalled inspectors from China due to the outbreak, which could possibly lead to delays in manufacturing...READ MORE

The COVID-19 pandemic is reshaping the global supply chain, and the Trump administration has a message for established generics drugmakers: Bring your manufacturing on shore, or we will find new companies that do...two recent contracts the U.S. government signed to bring drug manufacturing to American soil. But will companies follow?...The HHS’ Biomedical Advanced Research and Development Authority just inked a $354 million four-year deal with a company called Phlow to make generic medicine and active pharmaceutical ingredients in Virginia. The Department of Defense awarded a $138 million grant to ApiJect to expand U.S. production capability for prefilled syringes, following a $450 million deal the company won from the HHS...Both deals fall in the injectables category and involve significant investments to upgrade facilities and purchase future products. They both tap relatively new companies, which appear to be using innovative manufacturing technologies...Where does that leave traditional generic players such as Teva, Novartis’ Sandoz and Mylan? They may choose to join in...READ MORE

Associations representing generic drug makers, health insurers, pharmacy benefit managers and pharmacies have sent a letter to top administration and congressional leaders laying out how some policies and proposals to fight COVID-19 are making the situation worse...In an unusual display of coordinated frankness for the industry, a coalition representing generic drug makers, insurers, pharmacies and benefit managers told Vice President Mike Pence and congressional leaders that some policies in place or under consideration to fight COVID-19 are making it difficult and more expensive for patients to get some drugs...Signers of the letter are the Academy of Managed Care Pharmacy, America’s Health Insurance Plans, the Association for Accessible Medicines, the Blue Cross Blue Shield Association, the National Association of Chain Drug Stores, the National Association of Specialty Pharmacy, the Pharmaceutical Care Management Association and Pharmaceutical Research and Manufacturers of America...READ MORE

The new coronavirus outbreak may be very bad for your health but not only for the reasons you imagined. This coronavirus is less likely to harm you directly than to injure you through its impact on your other medical needs...COVID-19 is more likely to harm Americans indirectly because the U.S. is increasingly reliant on drugs either directly sourced from China or made from intermediate chemicals...While 90 percent of the finished drugs Americans take are generics, most are manufactured overseas, primarily in India and China. Even India...relies on China for 80 percent of the APIs it uses in drug production...COVID-19 has resulted in massive disruption of Chinese manufacturing. It’s only a matter of time until this translates into supply disruptions for China-dependent customers...Coronavirus has created concerns about not only the quantity of Chinese medical products available but also about the virus’s effect on quality. China does not effectively regulate Chinese drug manufacturers. Multiple episodes have cast doubt on the safety and efficacy of their products...READ MORE

Prescriptions for vaccines are suffering materially during the COVID-19 pandemic...It’s understandable that retail prescriptions of drugs have declined since COVID-19 hit the U.S., as patients refrain from visiting physicians. But still, some drugs are suffering terribly, while others appear to be holding steady...total prescriptions for drugs for acute use have plummeted by 28% since February...vaccines saw the most decline, probably because people stopped going to public spaces to address a disease they don’t even have...the autoimmune market, HIV and anticoagulants have so far experienced no impact...READ MORE

The specter of global drug shortages looms large amid the coronavirus pandemic. But so far, the supply chain is holding steady and prices are going up—in the generic drug business, at least. One analyst, in fact, figures COVID-19 could turn out to be a profitable time for the generics industry...After some "initial shocks" from COVID-19, the global generic drug supply chain is likely to rebound and deliver strong growth numbers despite some potential "spot shortages,"...A potent mixture of patient and channel stockpiling and manufacturer "allocation" measures will drive generics pricing upward in the short term...READ MORE

COVID-19's global spread has raised fears over drug shortages and price spikes, but Novartis' Sandoz is taking an early step to allay those concerns. The drugmaker, a top player in generics and off-patent antibiotics, pledged “stable” pricing for certain essential drugs and antibiotics amid the crisis...No matter how the supply chain situation plays out, Sandoz pledged to “keep prices stable for certain essential medicines it markets commercially," CEO Richard Saynor said in a statement...The commitment comes amid fears that the global supply chain will face disruption from an outbreak that’s so far taken its biggest toll in China, a manufacturing powerhouse where many of the pharmaceutical industry's starting materials are made...READ MORE